IONS - アイオニス・ファ―マシュ―ティカルズ (Ionis Pharmaceuticals Inc.) アイオニス・ファ―マシュ―ティカルズ

 IONSのチャート


 IONSの企業情報

symbol IONS
会社名 Ionis Pharmaceuticals Inc (アイオニス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イオニス・ファーマシューティカルズ(Ionis Pharmaceuticals Inc.)(旧名:Isis Pharmaceuticals Inc.)はリボ核酸標的(RNA標的)薬の発見・開発会社である。同社はアンチセンス薬の発見・開発に焦点を当てる。同社のアンチセンス薬は、心血管、代謝、神経疾患を含む重症・希少疾患、及び癌等疾患の治療に使用される。Volanesorsenは、家族制カイロミクロン血症(FCS)と呼ばれる遺伝子疾患を持つ患者及び限局性脂肪異栄養症を持つ患者を含む高トリグリセリドレベルを有する患者の治療のための薬である。同社は、後期フェーズIII薬、nusinersen、volanesorsenとIONIS-TTRを市場に導入することに焦点を当てる。同社の脂質低下製品KYNAMRO(ミポメルセンナトリウム)注射液は、米国市場でホモ接合型家族性高コレステロール血症(HoFH)を持つ患者に使用される。同社の製品はまたAlicaforsen、IONIS-DMPK-2.5、PlazomicinとIONIS-GCGRが含まれる。  アイオニス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主に治療用新化合物の発見・製造・販売に従事。同社製品には遺伝性高脂血症治療薬の「KYNAMRO」や、高トリグリセリド血症治療薬の「ISIS-APOCIIIRx」や「ISIS-FXIRx」がある。本社はカリフォルニア州サンディエゴ。   For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.
本社所在地 2855 Gazelle Court Carlsbad CA 92010 USA
代表者氏名 Stanley T. Crooke スタンリーT.クルーク
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 760-931-9200
設立年月日 32509
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 547人
url www.ionispharma.com
nasdaq_url https://www.nasdaq.com/symbol/ions
adr_tso
EBITDA EBITDA(百万ドル) -32.05600
終値(lastsale) 44.96
時価総額(marketcap) 6171834858.72
時価総額 時価総額(百万ドル) 6203.408
売上高 売上高(百万ドル) 555.37600
企業価値(EV) 企業価値(EV)(百万ドル) 4848.796
当期純利益 当期純利益(百万ドル) 67.31500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ionis Pharmaceuticals Inc revenues increased 19% to $262.2M. Net loss increased from $2.2M to $41.8M. Revenues reflect Akcea Therapeutics segment increase from $11.8M to $35.4M. Higher net loss reflects Ionis core segment income decrease of 63% to $40.5M Akcea Therapeutics segment loss increase of 13% to $93.8M Elimination of Intercompany Activity segment loss totaling $379K vs. income of $60K.

 IONSのテクニカル分析


 IONSのニュース

   Huntington Disease Protein Market Size Analysis, Industry Outlook, Regional Forecast 2021-2027| AFFiRiS AG, Ionis Pharmaceuticals, Inc., Neurimmune Holding AG  2021/09/03 11:52:46 OpenPR
Huntingtin is found in a large number of the body''s tissues, with the most elevated levels of action in the mind. Inside cells, this protein might be associated with substance flagging, shipping materials, connecting (restricting) to proteins and different constructions,
   Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting  2021/09/03 11:05:00 Business Insider Markets
CARLSBAD, Calif., Sept. 3, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today it will present 14 posters and two symposiums highlighting new scientific insights from its ATTR amyloidosis
   Ionis to present at upcoming virtual investor conferences  2021/09/02 11:05:00 Business Insider Markets
CARLSBAD, Calif., Sept. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following
   Hereditary ATTR (hATTR) Amyloidosis Market Impulsive Hikes by 2028 with Alnylam Pharmaceuticals, Akcea Therapeutics, Pfizer, Ionis Pharmaceuticals, Eidos Therapeutics, Corino Therapeutics Inc, Prothena  2021/08/27 09:42:33 OpenPR
Hereditary transthyretin-mediated (hATTR) amyloidosis is a rare, underdiagnosed, inherited, rapidly progressive, debilitating, and often fatal condition. It is caused by variants (i.e., mutations) in the transthyretin (TTR) gene. hATTR amyloidosis symptoms can vary from person to person, depending on which organs
   Lipodystrophy Syndrome (LS) Market 2021-2028 Healthcare Leads Massive Hike in Future with Ionis Pharmaceuticals, Zydus Cadila, Bristol-Myers Squibb  2021/08/27 09:33:51 OpenPR
Lipodystrophy is a group of rare disorders characterized by the abnormal utilization and storage of body fat. The most common signs of lipodystrophy are an abnormal distribution of body fat and an insatiable appetite. Lipodystrophy is a group of rare disorders
   What is behind the Rise of the Hereditary Angioedema Treatment Market by Top Key Players are BIOCRYST PHARMACEUTICALS INC., Ionis Pharmaceuticals Inc., Attune Medical, Arrowhead Pharmaceuticals Inc., and Adverum  2021/06/30 05:31:05 OpenPR
Hereditary Angioedema Treatment Market | 2021 Size, Growth, Share, Cap, Regional Analysis With Global Industry Forecast To 2027. The global Hereditary Angioedema Treatments market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled,
   Ionis Pharmaceuticals Stock Looks Attractive At $37  2021/06/29 23:05:37 Forbes
Ionis Pharmaceuticals Stock Looks Attractive At $37 Forbes
   Companies - Ionis Pharmaceuticals Stock Looks Attractive At $37  2021/06/23 12:47:05 BusinessMag
We believe that the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is undervalued at current
   Ionis'' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine  2021/06/14 20:05:00 PR Newswire
CARLSBAD, Calif., June 14, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C. Frank Bennett, Ph.D., is a co-recipient of the 23rd Jacob and Louise Gabbay Award in Biotechnology and Medicine for his
   Ionis Pharmaceuticals (IONS) Investor Presentation - Slideshow  2021/06/11 18:32:53 Seeking Alpha
   Ionis'' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine  2021/06/14 20:05:00 PR Newswire
CARLSBAD, Calif., June 14, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C. Frank Bennett, Ph.D., is a co-recipient of the 23rd Jacob and Louise Gabbay Award in Biotechnology and Medicine for his
   Ionis Pharmaceuticals (IONS) Investor Presentation - Slideshow  2021/06/11 18:32:53 Seeking Alpha
   Ionis'' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting  2021/06/10 22:05:00 PR Newswire
CARLSBAD, Calif., June 10, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society
   Ionis announces changes to its board of directors at annual meeting of stockholders  2021/06/02 23:59:00 PR Newswire
CARLSBAD, Calif., June 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board. As previously announced,
   Ionis: Price Slump Is An Opportunity To Buy The Pipeline  2021/06/02 07:04:59 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アイオニス・ファ―マシュ―ティカルズ IONS Ionis Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)